Transaction value and cost construction upheld for physician samples; comparable-goods valuation rejected where genuine sales and loan licence manufacture applied.
Physician samples sold to contracting customers were held assessable on genuine transaction value under section 4(1)(a), because actual sales existed and the conditions for substituting comparable-goods valuation were not met. Physician samples manufactured on a loan licence basis from raw materials and packing materials supplied by the principal brand owner were also treated as properly valued on cost construction basis, as Rule 4 comparable-goods valuation was not the correct method for those clearances. The assessee's valuation approach was upheld, and the contrary Revenue demands were not sustained.
Issues: (i) Whether physician samples sold to contracting customers were to be valued on transaction value under section 4(1)(a) or on the basis of comparable goods under Rule 4 of the Central Excise Valuation Rules, 2000. (ii) Whether physician samples manufactured on loan licence basis from raw material and packing material supplied by the principal brand owner were to be valued under Rule 8 cost construction, or under Rule 4 of the Central Excise Valuation Rules, 2000.
Issue (i): Whether physician samples sold to contracting customers were to be valued on transaction value under section 4(1)(a) or on the basis of comparable goods under Rule 4 of the Central Excise Valuation Rules, 2000.
Analysis: Where excisable goods are actually sold and the transaction value is genuine, uninfluenced and satisfies the conditions of section 4(1)(a), valuation must follow that transaction value. Merely because the goods may also be capable of MRP-based assessment does not displace section 4A unless the statutory conditions for such assessment are met. Physician samples were not shown to be retail goods with MRP fixation, and the sales to the contracting customers constituted real sale transactions.
Conclusion: The samples sold to contracting customers were correctly assessable on transaction value, and not under Rule 4. This issue is decided in favour of the assessee.
Issue (ii): Whether physician samples manufactured on loan licence basis from raw material and packing material supplied by the principal brand owner were to be valued under Rule 8 cost construction, or under Rule 4 of the Central Excise Valuation Rules, 2000.
Analysis: For loan licence manufacture, the valuation adopted on cost construction basis was supported by the Supreme Court's treatment of identical valuation rules and by the accepted principle that where the relevant rules on comparable goods do not apply, the cost-based method remains proper. The record also showed that the comparable-goods approach under Rule 4 was not the correct basis for these clearances.
Conclusion: The loan licence clearances were correctly valued on cost construction basis, and Rule 4 could not be applied. This issue is decided in favour of the assessee.
Final Conclusion: The valuation adopted by the assessee for physician samples was upheld, the Revenue's contrary demands were not sustained, and all connected appeals of the assessee succeeded while the Revenue's appeals failed.
Ratio Decidendi: Where excisable goods are actually sold on a genuine transaction value satisfying section 4(1)(a), that value governs assessment, and Rule 4 comparable-goods valuation cannot displace it merely because the goods are physician samples or are capable of another valuation method.